Hepatitis C Drugs on Medicare: Harvoni, Mavyret, and Epclusa

Hepatitis C used to be a chronic, sometimes life-shortening infection. Today a short course of direct-acting antiviral drugs can cure it in most people, often in eight to twelve weeks. The catch has always been cost, because these drugs carry some of the highest list prices in medicine. For Medicare beneficiaries, the good news is that a major change to Part D that began in 2025 has dramatically reshaped what a cure actually costs out of pocket. Here is how these drugs are covered and why the math is different now.

Bryce's Take

This is one of my favorite examples of the $2,000 cap doing exactly what it was meant to do. A hepatitis C cure used to be something people would put off because of the cost, even with insurance. Now it is a short course with a known ceiling, and for a lot of my clients it means the difference between treating the disease and living with it. If you are looking at one of these antivirals, let us make sure your specific plan covers the drug your doctor wants and time it sensibly within the year.

How hepatitis C drugs are covered

Direct-acting antivirals for hepatitis C, including drugs like Harvoni, Mavyret, and Epclusa, are self-administered pills you take at home, so Medicare covers them under Part D, your prescription drug coverage. Because they carry very high list prices, Part D plans almost always place them on a specialty tier, the highest cost tier, where cost-sharing is typically a percentage of the drug's price rather than a flat copay. On paper, a percentage of a drug that can list in the tens of thousands of dollars for a full course looks alarming, which is exactly why the recent change to Part D matters so much here.

The $2,000 Part D cap changed everything

Beginning in 2025, Part D has an annual out-of-pocket cap of $2,000. Once your covered Part D cost-sharing reaches $2,000 in a plan year, you pay nothing more for covered drugs for the rest of that year. For a short, extremely expensive course of treatment like a hepatitis C cure, this is transformative. Instead of facing open-ended coinsurance on a drug with a huge list price, your total out-of-pocket cost for covered Part D drugs that year is limited to $2,000. For a beneficiary who is otherwise healthy and taking few other drugs, that means a curative course of therapy now has a known, capped ceiling.

Why the timing of a short course matters

Because a hepatitis C cure is typically a short course of eight to twelve weeks rather than an ongoing medication, and because the drug is so expensive, many people will hit the $2,000 cap early in the treatment and then pay nothing more for covered drugs for the rest of the calendar year. If you take other Part D drugs, those costs count toward the same $2,000 cap, so once you have cleared it for hepatitis C treatment, your other covered drugs are effectively covered for the remainder of the year too. Where the course falls in the calendar year can affect how this plays out, which is a detail worth thinking through.

Formulary placement and prior authorization

Even with the cap protecting your total exposure, it still matters which specific hepatitis C drug your plan covers and on what terms. Plans differ in which of these antivirals they include on their formulary, and they commonly require prior authorization before covering them, sometimes with clinical criteria around your specific genotype or liver status. Your prescriber handles the prior authorization, but knowing your plan covers the exact drug your doctor wants to use, and confirming any requirements up front, prevents delays in starting a time-limited course of treatment.

Facing hepatitis C treatment on Medicare?

The $2,000 Part D cap turned a once open-ended cost into a known ceiling, but plan formularies and prior authorization still vary. Let me confirm your plan covers the drug your doctor wants before you start.

Book a Free Call

What this means for you

The bottom line is encouraging: a hepatitis C cure that once carried the risk of enormous out-of-pocket cost is now capped for Medicare beneficiaries by the $2,000 annual Part D limit. Your exact cost still depends on your specific plan's formulary, the drug your doctor prescribes, and where the course falls in the year, but the ceiling is far more predictable than it used to be. If you are facing hepatitis C treatment, it is worth confirming your plan covers the drug well before you begin.

Frequently asked questions

Are hepatitis C drugs covered by Medicare?

Yes. Direct-acting antivirals like Harvoni, Mavyret, and Epclusa are self-administered pills, so Medicare covers them under Part D. Because of their high list prices, plans typically place them on a specialty tier, and coverage and prior authorization requirements vary by plan.

How much do hepatitis C drugs cost on Medicare now?

Your total covered Part D cost-sharing is capped at $2,000 per year beginning in 2025. Because a hepatitis C cure is an expensive short course, many people reach that cap and then pay nothing more for covered drugs that year. Your exact cost depends on your plan and the drug prescribed.

Does the $2,000 cap really apply to a hepatitis C cure?

Yes. The cap applies to all covered Part D drugs combined, including expensive specialty drugs like hepatitis C antivirals. Once your covered cost-sharing reaches $2,000 in a plan year, you pay nothing more for covered drugs for the rest of that year.

Do hepatitis C drugs require prior authorization?

Frequently, yes. Part D plans commonly require prior authorization for these high-cost antivirals, sometimes with clinical criteria tied to your genotype or liver status. Your prescriber handles the request, but confirming your plan covers the exact drug and any requirements up front helps avoid delays.

Does it matter when in the year I start treatment?

It can. The $2,000 cap resets each January, so where a short expensive course falls in the calendar year affects how your costs and any other Part D drugs interact with the cap. Thinking through the timing with your plan in mind is worthwhile for a time-limited course.

Bryce Casson

Licensed Independent Medicare Broker

Bryce Casson is an independent Medicare insurance broker who works with every major carrier. He does not represent any single insurer, which means his recommendations are based on what actually fits each client's situation, not on commissions or quotas.